A-674563
Catalog No. A11034
A-674563是一种B/Akt抑制剂,IC50为14 nM,并且还显示出对PKA和CDK2的抑制活性,IC50分别为16和46 nM。
- Kobayashi T, .et al. A-674563 increases chondrocyte marker expression in cultured chondrocytes by inhibiting Sox9 degradation, Biochem Biophys Res Commun, 2018, Jan 1;495(1):1468-1475 PMID: 29196261
- Lin Xu, .et al. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells, Biochem Biophys Res Commun, 2016, Apr 15;472(4):662-8 PMID: 26920060
- Zou Y, .et al. Pre-clinical assessment of A-674563 as an anti-melanoma agent, Biochem Biophys Res Commun, 2016, Aug 12;477(1):1-8 PMID: 26970307
Catalog Num | A11034 |
---|---|
M. Wt | 358.4 |
Formula | C22H22N4O |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 552325-73-2 |
Synonyms | A674563 |
SMILES | CC1=C2C=C(C=CC2=NN1)C3=CC(=CN=C3)OC[C@H](CC4=CC=CC=C4)N |
A-674563是一种B/Akt抑制剂,IC50为14 nM,并且还显示出对PKA和CDK2的抑制活性,IC50分别为16和46 nM。
Targets
Target | Value |
---|---|
Akt1 | ki: 11nM |
PKA | ki: 16nM |
CDK2 | ki: 46nM |
GSK-3β | ki: 110nM |
ERK2 | ki: 260nM |
PKCδ | ki: 360nM |
RSK2 | ki: 580nM |
MAPK-AP2 | ki: 1.1μM |
PKCγ | ki: 1.2μM |
FLT1 | ki: >2.2μM |
Chk1 | ki: 2.6μM |
KDR | ki: >3.7μM |
CK2 | ki: 5.4μM |
c-Kit | ki: >5.8μM |
Src | ki: 13μM |
PDK-1 | ki: >20μM |
In vitro (25°C) | DMSO | 71 mg/mL (198.08 mM) | |
Water | 71 mg/mL (198.08 mM) | ||
Ethanol | 18 mg/mL (50.21 mM) | ||
In vivo | Saline | 28 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 27.9 mL | 139.51 mL | 279.02 mL |
0.5 mM | 5.58 mL | 27.9 mL | 55.8 mL |
1 mM | 2.79 mL | 13.95 mL | 27.9 mL |
5 mM | 0.56 mL | 2.79 mL | 5.58 mL |
*The above data is based on the productmolecular weight 358.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.